<DOC>
	<DOC>NCT01633723</DOC>
	<brief_summary>DA-6886_IBS_I is a phase I, dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose escalation clinical trial with open-labelled food effect study of single dose to investigate the safety, tolerability and pharmacokinetics of DA-6886 after oral administration in healthy male subjects.</brief_summary>
	<brief_title>Phase I Clinical Trial of DA-6886 in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>20 ~ 45 years old 27kg/m2 ≥ BMI ≥ 20kg/m2 Healthy Male Informed consent Clinically significant medical history smokers Clinically significant hypersensitivity of Drugs Clinically significant cutaneous disorder QTcB &gt; 450msec have a history of drug abuse or show positive for drug abuse or cotinine at urine screening</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>